Australian CDMO Ab Initio Pharma has announced the opening of a new R&D facility in Sydney, which the company says is “fitted out to provide state-of-the-art testing and R&D services to Australian and overseas companies developing innovative therapeutics.” Ab Initio also has a GMP manufacturing facility that was granted a license by the TGA in 2022 to manufacture a variety of dosage forms including DPIs, MDIs, SMIs, and nasal sprays.
Ab Initio Chief Scientific Officer Hui Xin Ong commented, “The expansion of Ab Initio onto this new site will provide us with significantly increased capacity for our clients and allow us to accelerate client projects bringing them into the clinic faster.”
Chief Operations Officer, William Glover said, “The move to Macquarie Park will enable us to build new relationships within this vibrant innovation district while continuing to expand and build on relationships with our existing partners. Ab Initio has grown rapidly over the past 2 years and the move to this new site will allow us to accommodate our current expansion plans.”
Read the Ab Initio Pharma announcement.
